Table 3. Clinical trial progress of in vivo CAR-T cells for the treatment of hematological malignancies and solid tumors via clinicaltrial.gov.
| Drug Name | Target CARs | Platform | Indication | Phase | Primary Outcomes | Company | Status | NCT Number |
|---|---|---|---|---|---|---|---|---|
| JY231 | CD19 | Anti-CD3 decorated lentivirus | R/R B-cell malignancies | IIT | MTD, incidence of AE after infusion | Shenzen Genocury Ltd. | Recruiting | NCT07065279 |
| INT2104 | CD20 | Anti-CD7 scFv-decorated lentivirus | R/R B-cell malignancies | I | AE after infusion | Interius BioTherapeutics | Recruiting | NCT06539338 |
| UB-VV111 | CD19 | Multi-domain anti-CD3, CD80, CD58 decorate lentivirus | R/R B-cell malignancies | I | AE after infusion | Umoja Biopharma | Recruiting | NCT06528301 |
| UB-VV400 | CD22 | Multi-domain anti-CD3, CD80, CD58 decorate lentivirus | B-cell lymphoma | IIT | MTD | Umoja Biopharma | Recruiting | NCT06743503 |
| ESO-T01 | BCMA | Targeted lentiviral particles | R/R Multiple Myeloma | I | DLTs, CRS, TRAE | EsoBiotec | Recruiting | NCT06791681 NCT06691685 |
| OriV508 | CD19/BCMA | Lentivirus | R/R hematological malignancies | I | DLTs, CRS, TRAEs | Oricell Therapeutics | Recruiting | NCT07101705 |
| LVIVO-TaVec100 | CD19/CD20 | Not disclosed | R/R B-cell Malignancies | I | Incidence, severity and type of TEAEs, RP2D | Nanjing Legend Biotech | Recruiting | NCT07002112 |
| JCXH-213 | B cell-targeted CAR | tLCNP | R/R B-cell non-Hodgkin lymphoma | IIT | DLT | Immorna | Recruiting | NCT06618313 |
Note: Abb: CARs: Chimeric Antigen Receptors; R/R: Relapsed/Refractory; scFv: single-chain variable fragment; IIT: Investigator-Initiated Trial; MTD: Maximum Tolerated Dose; AE: Adverse Event; I: Phase I (Clinical Trial); BCMA: B-cell Maturation Antigen; DLTs: Dose-Limiting Toxicities; CRS: Cytokine Release Syndrome; TRAE: Treatment-Related Adverse Events; TEAEs: Treatment-Emergent Adverse Events; RP2D: Recommended Phase 2 Dose; tLCNP: targeted Lipid Nanoparticle.